0001209191-23-030819.txt : 20230518 0001209191-23-030819.hdr.sgml : 20230518 20230518192224 ACCESSION NUMBER: 0001209191-23-030819 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230516 FILED AS OF DATE: 20230518 DATE AS OF CHANGE: 20230518 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Feeley Kevin CENTRAL INDEX KEY: 0001944119 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39482 FILM NUMBER: 23937591 MAIL ADDRESS: STREET 1: C/O SEMA4 HOLDINGS CORP STREET 2: 333 LUDLOW STREET, NORTH TOWER, 8TH FL. CITY: STAMFORD STATE: CT ZIP: 06902 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: GeneDx Holdings Corp. CENTRAL INDEX KEY: 0001818331 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-HEALTH SERVICES [8000] IRS NUMBER: 851966622 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 333 LUDLOW STREET STREET 2: NORTH TOWER, 8TH FLOOR CITY: STAMFORD STATE: CT ZIP: 06902 BUSINESS PHONE: 617 780 8742 MAIL ADDRESS: STREET 1: 333 LUDLOW STREET STREET 2: NORTH TOWER, 8TH FLOOR CITY: STAMFORD STATE: CT ZIP: 06902 FORMER COMPANY: FORMER CONFORMED NAME: Sema4 Holdings Corp. DATE OF NAME CHANGE: 20210721 FORMER COMPANY: FORMER CONFORMED NAME: CM Life Sciences, Inc. DATE OF NAME CHANGE: 20200715 4 1 doc4.xml FORM 4 SUBMISSION X0407 4 2023-05-16 0 0001818331 GeneDx Holdings Corp. WGS 0001944119 Feeley Kevin C/O GENEDX HOLDINGS CORP. 333 LUDLOW ST, NORTH TOWER STAMFORD CT 06902 0 1 0 0 Chief Financial Officer 0 Class A Common Stock 2023-05-16 4 S 0 1516 6.4985 D 3856 D The sale reported on this Form 4 represents shares sold by the Reporting Person in a broker-assisted transaction to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.37 to $7.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 2 of this Form 4. All numbers presented above reflect share amounts after giving effect to the 33:1 reverse stock split the Issuer's stockholders approved on April 14, 2023, which was previously announced in the Current Report on Form 8-K filed by the Issuer on April 17, 2023, and which became effective on May 4, 2023. /s/ Bridget Brown, Attorney-in-Fact 2023-05-18